PLATFORM SPECIALTY PRODUCTS CORPORATION

Platform Specialty Products

Credit Suisse Basic Materials Conference

September 18, 2015



Safe Harbor

Please note that this presentation is intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In this presentation, we may discuss events or results that have not yet occurred or been realized, commonly referred to as "forward-looking statements" within the meaning of the federal securities laws. Such discussion and statements will often contain words as expect, anticipate, believe, intend, plan and estimate. Such statements include, but are not limited to, statements relating to Platform Specialty Products Corporation ("Platform")'s financial or operational results including earnings guidance, future capital expenditures, expenses, revenues, earnings, synergies, economic performance, indebtedness, financial condition, dividend policy, losses and future prospects; business and management strategies; and the effects of global economic conditions on Platform's business. Many factors may cause the actual results, performance or achievements of Platform to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements including, among other things, Platform's ability to close the proposed acquisitions of the Electronic Chemicals and Photomasks businesses ("EC and PM businesses") of OM Group, Inc. ("OMG") and of Alent plc ("Alent"); Platform's adjusted earnings per share, expected or estimated revenue; the outlook for Platform's markets and the demand for its products, estimated sales, segment earnings, net interest expense, income tax provision, restructuring and other charges, cash flows from operations, consistent profitable growth, free cash flow, future revenues and gross operating and adjusted EBITDA margin improvement requirement and expansion, organic net sales growth, bank debt covenants; the success of new product introductions, growth in costs and expenses; Platform's ability to identify, hire and retain executives and other employees with sufficient expertise; Platform's assessment of its internal control over financial reporting; the impact of commodities and currencies and Platform's ability to manage its risk in these areas; general business and economic conditions globally, industry trends, competition, changes in government and other regulations, including in relation to the environment, health and safety, taxation, labor relations and work stoppages, changes in political and economic stability, disruptions in business operations due to reorganization activities and interest rate and currency fluctuations; and the impact of acquisitions, divestitures, restructuring and other unusual items, including Platform's ability to successfully complete as well as integrate and obtain the anticipated results and synergies from its consummated, pending and future acquisitions. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those projected as a result of certain factors. A discussion of factors that could cause results to vary is included in periodic and other reports filed by Platform with the Securities and Exchange Commission, including under the heading "Risk Factors" in Platform's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2015. Platform undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This presentation also contains non-GAAP financial measures that may not be directly comparable to other similarly titled measures used by other companies, including EBITDA and adjusted EBITDA. For purposes of Regulation G, a non-GAAP financial measure is a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the statements of operations, balance sheets, or statements of cash flows of such company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. Pursuant to the requirements of Regulation G, Platform has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures in the Appendix of this presentation. These non-GAAP measures are provided because management of Platform uses these financial measures in monitoring and evaluating Platform's ongoing financial results and trends. Management uses this non-GAAP information as an indicator of business performance, and evaluates overall management with respect to such indicators. These non-GAAP measures should be considered in addition to, but not as a substitute for, measures of financial performance prepared in accordance with GAAP.

Historical financial information relating to Agriphar was obtained directly from Percival S.A., its privately-held former parent company. Although we believe it is reliable, this information has not been verified, internally or independently. Historical financial information relating to the Chemtura AgroSolutions business of Chemtura Corporation was derived from segment reporting in Chemtura Corporation's periodic reports and earnings press releases. Financial information for Arysta LifeScience Limited ("Arysta") was derived from Arysta's registration statement on Form F-1 filed with the SEC on September 9, 2014, which was withdrawn since Platform's acquisition of Arysta and should not be relied upon, and from Arysta's management. Historical financial information related to the EC and PM businesses was derived from OMG's management estimates. These businesses' method of calculating their Adjusted EBITDA differs from Platform's method of calculating Adjusted EBITDA. Historical financial information for Alent was derived from Alent's periodic reports and management estimates. Alent's method of calculating its Adjusted EBITDA also differs from Platform's method. In addition, Alent's financial information is prepared in accordance with non-GAAP that may or may not be comparable to Platform's financial statements. Consequently, there is no assurance that the financial results and information for Agriphar, Chemtura AgroSolutions, Arysta, the EC and PM businesses, or Alent contained in this presentation are accurate or complete, or representative in any way of Platform's actual and future results as a consolidated company.

Important Information

No Offer or Solicitation

This presentation is for information purposes only and is not intended to, and does not, constitute or form part of any offer or invitation, or the solicitation of an offer, to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Alent acquisition or otherwise. The Alent acquisition will be implemented solely pursuant to the terms of a scheme document, which will contain the full terms and conditions of the transaction, including details of how to vote in respect of the Alent acquisition. Any vote or other action in respect of the transaction should be made only on the basis of the information in the scheme document.

Important Additional Information

The shares of common stock of Platform to be issued in connection with the Alent acquisition ("New Platform Shares") have not been and are not expected to be registered under the Securities Act of 1933, as amended (the "Act") or under the securities laws of any state or other jurisdiction of the United States. It is expected that the New Platform Shares will be issued in reliance upon an exemption from the registration requirements of the Act, set forth in Section 3(a)(10) thereof. Shareholders of Alent (whether or not US persons) who are or will be affiliates (within the meaning of the Act) of Platform or Alent prior to, or of Platform after, the effective date will be subject to certain US transfer restrictions relating to the New Platform Shares received pursuant to the scheme of arrangement.

Platform reserves the right, subject to the prior consent of the U.K. Panel on Takeovers and Mergers and the terms of the Co-operation Agreement dated July 13, 2015, to elect to implement the Alent acquisition by way of a takeover offer (as such term is defined in the U.K. Companies Act 2006). Any securities to be issued in connection with such transaction may be issued in reliance on an exemption from the registration requirements of, or, alternatively, registered under the Act. If, in the future, Platform exercises its right to implement the transaction by way of a takeover offer in which New Platform Shares are to be issued in a manner that is not exempt from the registration requirements of the Act, Platform will file a registration statement with the SEC that will contain a prospectus with respect to the issuance of New Platform Shares. In this event, shareholders of Alent are urged to read these documents and any other relevant documents filed with the SEC, as well as any amendments or supplements to those documents, because they will contain important information, and such documents will be available free of charge at the SEC's website at http://www.sec.gov or by contacting Platform's Investor Relations department in writing at 1450 Centrepark Boulevard, Suite 210, West Palm Beach, Florida 33401.

None of the securities referred to in this presentation have been approved or disapproved by the SEC, any state securities commission in the United States or any other US regulatory authority, nor have such authorities passed upon or determined the adequacy or accuracy of the information contained in this presentation. Any representation to the contrary is a criminal offence in the United States.

No profit forecast or estimates

No statement contained herein (including any statement of estimated synergies) is intended as a profit forecast or estimate for any period and no statement contained herein should be interpreted to mean that earnings per Platform's share for the current or future financial years would necessarily match or exceed the historical published earnings per Platform's share.

Introduction to Platform Specialty Products

- ✓ Best-in-class, global diversified specialty chemicals
  - High-quality existing portfolio of businesses
  - Ripe opportunity for expansion
- ✓ Leadership positions in niche markets
- ✓ Focus on businesses defined by high cash flow margins and strong customer relationships (“Asset-Lite / High-Touch”)
- ✓ Compound earnings growth through:
  - Stable organic growth
  - Consistent, efficient conversion of earnings to cash
  - Strategic capital allocation to increase intrinsic value per share

Platform Timeline

PLATFORM SPECIALTY PRODUCTS CORPORATION

January
- NYSE Listing



April
- Chemtura AgroSolutions Acquisition Announced

May
- $300 Million PIPE (Private investment in Public Equity)

August
- Agriphar Acquisition Announced

October
- $300 Million Bank Loan
- Agriphar Acquisition Closed
- $650 Million PIPE (Private investment in Public Equity)
- Arysta Acquisition Announced

November
- Chemtura AgroSolutions Acquisition Closed
- $402 Million Equity Offering
- $405 Million Bank Loan

January
- $1.1 Billion Senior Notes
- €350 Million Senior Notes

February
- $500 Million Term Loan
- €83 Million Term Loan
- $150 million upsize to Revolving Credit Facility
- Arysta Acquisition Closed

June
- OMG Acquisitions Announced
- $483 Million Equity Offering

July
- Alent Acquisition Announced

2014 | **2015**

Platform End Market Evolution

Revenue[1] by Business Segment

($ in millions)

Platform including Acquisitions Announced in 2014 and 2015 YTD



2014 PF Revenue[1]: $3,778 million

Platform including Ag Acquisitions Announced in 2014



2014 PF Revenue: $2,926 million

Platform/MacDermid



2013 Revenue: $746 million

Note: For a reconciliation of non-GAAP financials, please refer to the appendices of this presentation.
Alent financials converted from GBP to USD at an average exchange rate over the 2014 fiscal year of 1.65.

1. Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
2. For the 2015 YTD Acquisitions, Performance Applications includes legacy Platform Performance Materials, Alent's Surface Chemistries and Assembly Materials, and OMG's EC and PM Businesses.

The “Asset-Lite, High-Touch” Business Model

PLATFORM SPECIALTY PRODUCTS CORPORATION

Asset-Lite

- Formulated Chemistry
- Capex less than 3% of Sales

+

High-Touch

- Significant, Highly Technical Sales Force
- SG&A greater than 20% of Sales
- People and Technology are the “Moat”

=

Superior Return on Capital

- Best-in-Class EBITDA less Capex Margins
- Industry Leading CFROI

Implications on Culture and Management

- Decentralized Management
- Significant Autonomy to Workforce
- R&D / Resource Prioritization
- Focus on People

Platform Pro Forma Cash Flow

Adj. PF EBITDA – CapEx[1] (% of PF Adj. EBITDA)



Note: Financials are non-GAAP. Please refer to the appendices of this presentation for reconciliation. 2009-2011 financials includes MacDermid, CAS and Arysta; 2012 - 2014 includes MacDermid, CAS, Arysta and Agriphar. Does not include Alent or OMG assets.

1. MacDermid and CAS prepared in accordance with US GAAP. Agriphar financials prepared in accordance with Belgium GAAP from 2012-2013 and US GAAP for 2014. Arysta financials prepared in accordance with Japanese GAAP from 2009 – 2011 and UG GAAP from 2012 – 2014. Arysta EBITDA includes Goemar for the historical 2012, 2013 and pre-acquisition 2014 period.
2. Cash conversion calculated based on (EBITDA – CapEx) / EBITDA.

Platform End Market Overview and Opportunity

Platform is executing a global build-up of high quality, high cash flow specialty chemical businesses across a diverse range of verticals



Source: Assembly Materials market opportunity from Prismark and Alent management analysis. Other market opportunities from Platform management.
Note: Assembly Materials market opportunity converted from GBP to USD at 1.55 exchange rate as of 7/10/2015.

Announced Acquisition Status Update

PLATFORM SPECIALTY PRODUCTS CORPORATION

	Announced	Purchase Price	Financing	Regulatory	Expected Closing
OMG EC and PM Businesses	June 2015	$367 million	▪ $483 million cash on hand from equity raise in July 2015	▪ All carve-out approvals received ▪ Apollo still awaiting certain approvals for OMG acquisition	▪ Q4 2015 ▪ Q1 2016 (second transaction)
ALENT	July 2015	$2.25 billion[1]	▪ $465 million of shares, based on PAH share price at announcement of $24.76 [2] ▪ $1.9 billion in committed debt financing	▪ US, South Korea, Germany, and Brazil approvals in place ▪ Other regulatory filings proceeding as planned ▪ Alent shareholder approval obtained early in Sept.	Q4 2015 or Q1 2015

1. Based on enterprise value of Alent and on Platform share price at announcement of $24.76.
2. Based on Platform share price of US$24.76, being the VWAP on 7/10/2015 and a GBP / USD FX rate of 1.5517.

Pro Forma Platform Financial Profile
Platform + Alent + OMG

PF Revenue[1]

($ in millions)



PF Adjusted EBITDA and Margin

($ in millions)



PF CapEx

($ in millions)



PF EBITDA – CapEx

($ in millions)



For a reconciliation of non-GAAP financials, please refer to the appendices of this presentation.

Note: Alent financials converted from GBP to USD at average exchange rate over the year. 2012: 1.59; 2013: 1.56; 2014: 1.65.
OMG Financials provided by OMG management.

1. Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by the Divisions.
2. Alent 2012 CapEx excludes $9 million relating to the purchase of land and buildings.

2014 Regional Sales Footprint

PLATFORM SPECIALTY PRODUCTS CORPORATION

Diversified, global footprint balancing emerging markets and developed economies

Pro Forma Agricultural Solutions



Pro Forma Performance Applications



Combined Platform Pro Forma
$3,778 million



Source: Alent 2014 Annual Report, OMG and Platform management.

Significant Synergy Potential

- $50 million[(1)] of estimated synergies from Alent combination
- $20 million* of additional expected synergies from OMG EC and PM businesses
- $5 million* of Agricultural Solutions synergies realized in same quarter as Arysta close



Agricultural Solutions Estimated Synergies

General & Administrative
- Shared services implementation
- Overlapping leadership positions

Distribution
- Owned distribution lines vs. third-party outsourced
- Increased efficiency

Other COGS
- Procurement & logistics
- Economies of scale
- Manufacturing / tolling

OMG EC & PM Estimated Synergies
- Overlapping production capabilities
- G&A overlap with Performance Applications
- Increased efficiency

Alent Estimated Synergies

COGS – $12 million
- Optimizing production
- Purchasing

SG&A – $38 million
- Corporate and G&A overhead
- Supply chain overlap

Source: Management estimates.
Note: Figures marked with an * are not quantified benefits statement for the purposes of the UK Takeover Code because they do not depend upon the success of the offer for Alent.
1. These estimated synergies have been made in accordance with, and reported on under, the UK Takeover Code by PricewaterhouseCoopers LLP and Credit Suisse. Further details on the synergies and copies of their letters are included in the announcement published by Platform on July 13, 2015 and the related scheme document dated August 17, 2015 which all can be found at www.platformspecialtyproducts.com.

Financing Considerations

Secured debt capacity well in excess of current financing requirements

Illustrative Financing EBITDA Build



Illustrative First Lien Capacity



For a reconciliation of Non-GAAP financials, please refer to the appendices of this presentation.
Alent EBITDA converted from GBP to USD at an average exchange rate over the LTM period of 1.58.

1. Per OMG management.
2. Based on $150 million in total announced synergies less $13 million already realized and included in Platform LTM.
3. Based on 4.5x $941 million of financing EBITDA.

Platform Specialty Products Overview

- ✓ Best-in-class, global diversified specialty chemicals
  - High-quality existing portfolio of businesses
  - Ripe opportunity for expansion
- ✓ Leadership positions in niche markets
- ✓ Focus on businesses defined by high cash flow margins and strong customer relationships (“Asset-Lite / High-Touch”)
- ✓ Compound earnings growth through:
  - Stable organic growth
  - Consistent, efficient conversion of earnings to cash
  - Strategic capital allocation to increase intrinsic value per share

Questions


PLATFORM SPECIALTY
PRODUCTS CORPORATION
Performance Applications
Agricultural Solutions
MacDermid
OM Group
ALENT
EC and PM
Businesses
Chemtura
AGROSOLUTIONS
AGRIPHAR
Arysta LifeScience

PLATFORM SPECIALTY
PRODUCTS CORPORATION

Appendix: Recent Acquisition Overviews



OM Group Electronic Chemicals and Photomasks Acquisition Overview

- On June 1, 2015, Platform announced it had signed definitive agreements to acquire OMG's Electronic Chemicals ("EC") and Photomasks ("PM") businesses for $367 million in two separate and distinct transactions
- These businesses are highly-complementary and synergistic businesses aligned with Platform's core electronic chemicals assets
- Platform's $367 million purchase price represents a 13.0x multiple of EBITDA[(1)] before synergies and 7.6x multiple of EBITDA[(1)] after run-rate synergies of $20 million
- The transaction:
  - *Funds affiliated with Apollo Management VIII, L.P. ("Apollo") will purchase OMG in its entirety*
  - *Platform will subsequently acquire the EC and PM businesses from Apollo in two separate and distinct transactions*
  - *Platform's acquisition is expected to close in two separate and distinct transactions:*
    - *The first transaction (acquisition of the EC and PM businesses, other than their Malaysian subsidiary) is expected to close immediately after the close of the Apollo transaction*
    - *The second transaction (acquisition of the Malaysian subsidiary) is expected to occur in Q1 2016, subject to distinct closing conditions*
- The transaction has cleared most major hurdles to completion including a go-shop period, HSR review, and shareholder vote
- First close is expected in Q4 2015

1. 2014 OMG EC & PM segments EBITDA of $28 million; post-synergies EBITDA includes expected $20 million of synergies.

OMG EC & PM Overview

PLATFORM SPECIALTY PRODUCTS CORPORATION

OMG EC and PM Businesses

Electronic Chemicals (EC)
~$135m Revenue in 2014
~$25m EBITDA in 2014

- Leading developer and producer of proprietary wet metal-based specialty chemicals for high-end electronics
- Primary applications include electro-less and electrolytic plating (deposition of a thin layer of metal onto a substrate) and general metal finishing

Key End Markets

- Printed Circuit Boards
- Memory Disk
- General Metal Finishing
- Advanced Packaging
- Photovoltaics







Compugraphics (PM)
~$36m Revenue in 2014
~$3m EBITDA in 2014

- Develops, manufactures, markets and sells photomasks and reticles in North American and Europe
- Primarily focused on mature technology and mainstream production markets

Key End Markets

- Semiconductors
- Optoelectronics
- Microelectronics





Source: OM Group Management.

Alent Acquisition: Strategic Rationale

- Highly complementary businesses
- Augments legacy MacDermid capabilities, technology and geography
- Adds attractive new assembly materials business to Performance Applications product segments
- Exemplary “Asset-Lite, High-Touch” business model
- Similar “bookends” strategy with emphasis on innovation and technical service
- Enhanced geographic footprint
- Significant synergy potential through integration

Alent Transaction Summary

PLATFORM SPECIALTY PRODUCTS CORPORATION

- Platform has announced a recommended offer to acquire the entire issued share capital of Alent

Offer value	■ £5.03 per share ■ Offer represents a total Alent enterprise value of $2.25 billion[1]
Structure	■ 78% cash and 22% stock ■ Cash offer with partial share alternative for 22% of Alent shares ■ Partial share alternative exchange ratio of 0.31523 Platform shares[2] ■ Hard irrevocable undertaking from Cevian (22% shareholder in Alent) to elect for the share alternative in respect of their entire holding in Alent
Timing	■ Expected to close late 2015 or early 2016
Expected synergies[3]	■ $50 million of annual pre-tax cost synergies

1. Based on GBP / USD FX rate of 1.5517 at Platform market close on 7/10/2015.
2. Based on Platform share price of US$24.76, being the VWAP on 7/10/2015 at a GBP / USD FX rate of 1.5517.
3. These estimated synergies have been made in accordance with, and reported on under, the UK Takeover Code by PricewaterhouseCoopers LLP and Credit Suisse. Further details on the synergies and copies of their letters are included in the announcement published by Platform on July 13, 2015 and the related scheme document dated August 17, 2015 which all can be found at www.platformspecialtyproducts.com.

Alent Business Overview

PLATFORM SPECIALTY PRODUCTS CORPORATION

Segment	Key Products	End-market
Assembly Materials (ALPHA)	**Electronic interconnect materials** ■ Printed circuit board assembly ■ Semiconductor packaging	**Predominantly Electronics Industry Focused**
Surface Chemistries (ENTHONE)	**Specialty electroplating chemicals** ■ Semiconductor fabrication ■ Printed circuit board fabrication ■ Corrosion, wear-resistant, and decorative coatings	**Serving Mainly the Electronics and Automotive/ Industrial Industries**

Bringing Metals & Chemistry Together

A global supplier of specialty chemicals and engineered materials

Source: Alent March 2015 corporate presentation.

Alent Financial Overview

Revenue (NSV)[1]

($ in millions)



Adjusted EBITDA

($ in millions)



EBITDA – CapEx

($ in millions)



CapEx

($ in millions)



Note: For a reconciliation of non-GAAP financials, please refer to the appendices of this presentation.
Alent financials converted from GBP to USD at average exchange rate over the year. 2012: 1.59; 2013: 1.56; 2014: 1.65.

1. Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
2. Alent 2012 CapEx excludes $9 million relating to the purchase of land and buildings.

Alent Enhances the Performance Applications Segment

2014 Revenue(1)

($ in millions)



2014 EBITDA

($ in millions)



PF Sales (By Geography)(1)



PF Sales (By End Market)



Note: For a reconciliation of non-GAAP financials, please refer to the appendices of this presentation.
PF Platform and Alent excludes OMG's EC and PM businesses.
Alent financials converted from GBP to USD at an average exchange rate over the 2014 fiscal year of 1.65.
Alent EBITDA includes $12 million of corporate costs.

1. Alent reporting requires sales to be reported net of metal content which is the same as Net Sales Value (NSV). NSV is defined as revenue less commodity metals that pass through to customers. Commodity metals include gold, silver, tin, palladium, ruthenium, platinum and other metals as defined by Alent's Divisions.
2. Performance Applications represents consolidated Platform less the Agricultural Solutions Segment and includes corporate overhead costs for Platform in 2014.

PLATFORM SPECIALTY PRODUCTS CORPORATION

Appendix: Reconciliations to GAAP Financials



Platform Reconciliation of Net Loss to Adjusted EBITDA for 6 months ended June 30, 2015

($ in millions)

	June 30, 2015
Net (loss) available to common stockholders	($39)
Adjustments to reconcile net (loss) to Adjusted EBITDA:	
Interest expense	$93
Income tax expense	25
Depreciation and amortization expense	114
Restructuring and related expenses	14
Manufacturer's profit in inventory adjustment	57
Acquisition transaction costs	55
Non-cash fair value adjustment to contingent consideration	4
Legal settlement	(16)
Acquisition put option settlement	(3)
FX gains	(6)
Non-controlling interests	4
Other expense, net	(4)
Adjusted EBITDA	**$298** (1)

1. Excludes $3 million of EBITDA from Arysta prior to the close of the acquisition.

MacDermid Reconciliation of Net Income to Adjusted EBITDA Predecessor/Successor Combined

($ in millions)	December 31, 2012	2013	2014	
Net income (loss) available to common stockholders	$46	($181)	($7)	
Adjustments to reconcile net income (loss) to Adjusted EBITDA:				
Interest expense	$50	$52	$36	
Income tax expense	25	7	(3)	
Depreciation and amortization expense	42	46	76	(1)
FX gain	–	–	–	
Manufacturer's profit in inventory adjustment	–	24	12	(2)
Non-cash fair value adjustment to contingent consideration	–	(1)	29	(3)
Preferred dividend valuation	–	172	–	(4)
Acquisition costs	–	32	48	(5)
Debt extinguishment	–	19	–	(6)
Impairments	–	–	–	
Other expense, net	(1)	10	5	
Adjusted EBITDA	**$162**	**$180**	**$196**	

1. Includes $31 million and $57 million in 2013 and 2014, respectively, for amortization expense related to intangible assets recognized in purchase accounting for the MacDermid Acquisiton.
2. Adjustment to reverse manufacturer's profit in inventory purchase accounting adjustment associated with MacDermid Acquisition.
3. Adjustment to fair value of contingent consideration in connection with the MacDermid Acquisition primarily associated with achieving the share price targets.
4. Non-cash charge related to preferred stock dividend rights.
5. Adjustment to reverse deal costs primarily in connection with the MacDermid Acquisition for 2013 and the Chemtura, Arysta and Agriphar Acquisitions for 2014. The Arysta Acquisition closed in 2015.
6. Adjustment to reverse debt extinguishment charge in 2013 in connection with debt incurred as a result of a recapitalization.

Arysta Reconciliation of Net Loss to Adjusted EBITDA

($ in millions)	December 31, 2012	2013	2014	
Net (loss) available to common stockholders	($157)	($102)	($26)	
Adjustments to reconcile net (loss) to Adjusted EBITDA:				
Interest expense	$136	$135	$116	
Income tax expense	45	48	50	
Depreciation and amortization expense	74	67	68	
Other credit agreement adjustments	34	36	35	(1)
FX loss	37	40	17	
Impairments	–	49	35	(2)
Derivatives losses	31	1	–	
Discontinued operations	72	10	(2)	(3)
Non-controlling interests	9	9	9	
Other expense, net	(2)	(1)	(1)	
U.S. GAAP adjustment	(11)	7	(8)	
Adjusted EBITDA	**$268**	**$299**	**$293**	(4)

1. Adjustments provided for in credit agreement to compute Adjusted EBITDA.
2. Adjustment to reverse non-cash impairments of product registration rights of $48 million and $20 million and goodwill of $0 and $15 million during 2013 and 2014, respectively.
3. Includes discontinued operations for the Midas business and FES group of companies.
4. Goemar acquisition is included as a pro forma adjustment in 2012, 2013 and the pre-acquisition period of 2014.

Chemtura AgroSolutions
Reconciliation of Net Income to Adjusted EBITDA

($ in millions)	December 31, 2012	2013	2014	
Net income available to common stockholders	$39	$47	$25	
Adjustments to reconcile net income to Adjusted EBITDA:				
Interest expense	$1	–	$2	
Income tax expense	18	29	40	
Depreciation and amortization expense	15	14	19	(1)
FX loss (gain)	–	8	(4)	
Manufacturer's profit in inventory adjustment	–	–	14	(2)
Other expense, net	6	3	7	
Adjusted EBITDA	**$79**	**$101**	**$103**	

1. Includes $7 million of amortization related to intangibles recognized in purchase accounting in 2014.
2. Includes $14 million of inventory step up recognized in purchase accounting in 2014.

Agriphar
Reconciliation of Net Income to Adjusted EBITDA

($ in millions)	December 31, 2012	2013	2014	
Net income available to common stockholders	$19	$24	$13	
Adjustments to reconcile net income to Adjusted EBITDA:				
Interest expense	$2	$2	$1	
Income tax expense	9	11	7	
Depreciation and amortization expense	4	4	8	(1)
FX gain	–	–	(1)	
Manufacturer's profit in inventory adjustment	–	–	9	(2)
Other expense, net	1	–	7	
U.S. GAAP adjustment			6	
Adjusted EBITDA	**$35**	**$41**	**$50**	

Note: Numbers are presented in Belgium GAAP for 2012 and 2013. and US GAAP for 2014. 2012 Agriphar financials are unaudited.
1. Includes $3 million of amortization related to intangibles recognized in purchase accounting in 2014.
2. Includes $9 million of inventory step up recognized in purchase accounting in 2014.

Alent Reconciliation of Net Income to Adjusted EBITDA

(£ in millions)	December 31, 2012	2013	2014
Net income available to shareholders	£45	£62	£47
Adjustments to reconcile net income to Adjusted EBITDA:			
Pro forma adjustment to operating profit before JVs and exceptionals	(6)	–	–
Depreciation	9	9	9
Share of post-tax joint venture profit	(0)	(1)	(2)
Exceptional items(1)	16	10	18
Demerger costs	11	–	–
Net finance costs	4	7	5
Income tax costs	28	16	27
Adjusted EBITDA	**£106**	**£103**	**£104**

Note: Numbers are presented in IFRS.

1. Includes $4 million, $10 million and $8 million in 2012, 2013 and 2014, respectively, for restructuring; includes $7 million loss on construction contract in 2012; includes $7 million of litigation and settlement charges in 2014; includes $6 million and $3 million of disposal and closure costs in 2012 and 2014, respectively; includes $2 million of impairment charges in 2014; includes $2 million of litigation settlement income in 2014; includes $0.2 million of profit on disposal of operations in 2014.